WO1999007869A1 - Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite - Google Patents

Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite Download PDF

Info

Publication number
WO1999007869A1
WO1999007869A1 PCT/US1997/013836 US9713836W WO9907869A1 WO 1999007869 A1 WO1999007869 A1 WO 1999007869A1 US 9713836 W US9713836 W US 9713836W WO 9907869 A1 WO9907869 A1 WO 9907869A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
virus
recombinant
mice
mva
Prior art date
Application number
PCT/US1997/013836
Other languages
English (en)
Inventor
Parker A. Small, Jr.
Bradley Stephen Bender
Catherine Ann Meitin
Bernard Moss
Original Assignee
University Of Florida
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida, The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services filed Critical University Of Florida
Priority to PCT/US1997/013836 priority Critical patent/WO1999007869A1/fr
Priority to AU39100/97A priority patent/AU3910097A/en
Publication of WO1999007869A1 publication Critical patent/WO1999007869A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un vaccin du virus de la vaccine recombinant et servant à immuniser des animaux et des hommes contre une maladie. Ce vaccin comprend un virus de la vaccine vivant ou une réplication du virus de la vaccine mitante déficient, mais capable d'exprimer un ou plusieurs gènes ou fragments de gènes hétérologues. Selon une réalisation préférée, le virus recombinant est contenu dans une enveloppe d'administration orale qui ne se dissout que dans l'intestin de l'animal hôte. L'invention concerne également un procédé permettant d'induire une large réponse immunitaire protectrice par administration par voie orale, intranasale ou autrement muqueuse, du vaccin du virus de la vaccine recombinant.
PCT/US1997/013836 1997-08-05 1997-08-05 Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite WO1999007869A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US1997/013836 WO1999007869A1 (fr) 1997-08-05 1997-08-05 Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite
AU39100/97A AU3910097A (en) 1997-08-05 1997-08-05 Live recombinant vaccine comprising inefficiently or non-replicating vir us

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/013836 WO1999007869A1 (fr) 1997-08-05 1997-08-05 Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite

Publications (1)

Publication Number Publication Date
WO1999007869A1 true WO1999007869A1 (fr) 1999-02-18

Family

ID=22261399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013836 WO1999007869A1 (fr) 1997-08-05 1997-08-05 Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite

Country Status (2)

Country Link
AU (1) AU3910097A (fr)
WO (1) WO1999007869A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
US7189536B2 (en) 2000-11-23 2007-03-13 Bavarian Nordic A/S Modified vaccinia ankara virus variant
EP1465658B1 (fr) * 2002-01-15 2007-05-02 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. VACCINATION ORALE AVEC LE MIMOTOPE D'ANTIGENE Gln-Met-Trp-Ala-Pro-Gln-Trp-Gly-Pro-Asp
EP1327450B1 (fr) * 2002-01-15 2007-08-15 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vaccination orale par des mimotopes d'antigene tumoraux dénudés
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7695939B2 (en) 2002-09-05 2010-04-13 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7759116B2 (en) 2001-12-04 2010-07-20 Bavarian Nordic A/S MVA virus vector expressing dengue NS1 protein
US7897156B2 (en) 2001-11-22 2011-03-01 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US8007781B2 (en) 2000-08-03 2011-08-30 The Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US9011866B2 (en) 2005-01-06 2015-04-21 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP3333265A1 (fr) * 2010-05-14 2018-06-13 Oregon Health & Science University Vecteurs hcmv et rhcmv recombinants et utilisations associées
US10532099B2 (en) 2016-10-18 2020-01-14 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US10760097B2 (en) 2011-06-10 2020-09-01 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US10995121B2 (en) 2014-07-16 2021-05-04 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
US11091779B2 (en) 2015-02-10 2021-08-17 Oregon Health & Science University Methods and compositions useful in generating non canonical CD8+ T cell responses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1333512A (en) * 1971-06-19 1973-10-10 Stickl A H Vaccine composition for oral smallpox inoculation
WO1989003429A1 (fr) * 1987-08-28 1989-04-20 Health Research Inc. Virus recombinant de la variole avicole
WO1992016616A1 (fr) * 1991-03-20 1992-10-01 Virogenetics Corporation Vaccin contre le poxvirus de recombinaison de la malaria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1333512A (en) * 1971-06-19 1973-10-10 Stickl A H Vaccine composition for oral smallpox inoculation
WO1989003429A1 (fr) * 1987-08-28 1989-04-20 Health Research Inc. Virus recombinant de la variole avicole
WO1992016616A1 (fr) * 1991-03-20 1992-10-01 Virogenetics Corporation Vaccin contre le poxvirus de recombinaison de la malaria

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENDER ET AL.: "Cytotoxic T lymphocyte activity induced by influenza vaccination in young and aged mice", VACCINES90, 1990, pages 69 - 73, XP002055083 *
BENDER ET AL.: "Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against Influenza", JOURNAL OF VIROLOGY, vol. 70, no. 9, September 1996 (1996-09-01), pages 6418 - 6424, XP002055082 *
BLANCOU ET AL.: "Oral Vaccination of the fox against rabies using a live recombinant vaccinia virus", NATURE, vol. 322, 1986, pages 373 - 375, XP002055040 *
MEITIN ET AL.: "Enteric immunization of mice against influenza with recombinant vaccinia", PROC. NATL. ACAD. SCIE. USA, vol. 91, November 1994 (1994-11-01), pages 11187 - 11191, XP002055039 *
SUTTER ET AL.: "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to inflenza virus", VACCINE, vol. 12, no. 11, 1994, pages 1032-1040, XP002019163 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758551B2 (en) 1999-10-20 2017-09-12 The Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US8007781B2 (en) 2000-08-03 2011-08-30 The Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
EP2204452A1 (fr) * 2000-11-23 2010-07-07 Bavarian Nordic A/S Variant du virus Modified Vaccinia Ankara
EP1335987B2 (fr) † 2000-11-23 2016-06-15 Bavarian Nordic A/S Variant modifie du virus de la vaccine ankara
US7384644B2 (en) 2000-11-23 2008-06-10 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US8236560B2 (en) 2000-11-23 2012-08-07 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7459270B2 (en) 2000-11-23 2008-12-02 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US8163293B2 (en) 2000-11-23 2012-04-24 Bavarian Nordic A/S Modified Vaccinia Virus Ankara for the vaccination of neonates
EP2202315A1 (fr) * 2000-11-23 2010-06-30 Bavarian Nordic A/S Variant modifié du virus de la vaccine ankara
US7189536B2 (en) 2000-11-23 2007-03-13 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7335364B2 (en) 2000-11-23 2008-02-26 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7892533B2 (en) 2000-11-23 2011-02-22 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US8470598B2 (en) 2000-11-23 2013-06-25 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7923017B2 (en) 2000-11-23 2011-04-12 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7939086B2 (en) 2000-11-23 2011-05-10 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7964395B2 (en) 2000-11-23 2011-06-21 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method
US8268325B2 (en) 2000-11-23 2012-09-18 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7964398B2 (en) 2000-11-23 2011-06-21 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method
US7964396B2 (en) 2000-11-23 2011-06-21 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method
US8372622B2 (en) 2000-11-23 2013-02-12 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US8268329B2 (en) 2000-11-23 2012-09-18 Bavarian Nordic A/S Modified Vaccinia ankara virus variant
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7897156B2 (en) 2001-11-22 2011-03-01 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US8815501B2 (en) 2001-12-04 2014-08-26 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
US7759116B2 (en) 2001-12-04 2010-07-20 Bavarian Nordic A/S MVA virus vector expressing dengue NS1 protein
EP1465658B1 (fr) * 2002-01-15 2007-05-02 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. VACCINATION ORALE AVEC LE MIMOTOPE D'ANTIGENE Gln-Met-Trp-Ala-Pro-Gln-Trp-Gly-Pro-Asp
EP1327450B1 (fr) * 2002-01-15 2007-08-15 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vaccination orale par des mimotopes d'antigene tumoraux dénudés
US7964397B2 (en) 2002-09-05 2011-06-21 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7695939B2 (en) 2002-09-05 2010-04-13 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US8329466B2 (en) 2002-09-05 2012-12-11 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US8673318B2 (en) 2002-09-05 2014-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US9011866B2 (en) 2005-01-06 2015-04-21 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP3333265A1 (fr) * 2010-05-14 2018-06-13 Oregon Health & Science University Vecteurs hcmv et rhcmv recombinants et utilisations associées
US11266732B2 (en) 2010-05-14 2022-03-08 Oregon Health & Science University Recombinant HCMV and RHCMV vectors and uses thereof
US10760097B2 (en) 2011-06-10 2020-09-01 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US11692012B2 (en) 2014-07-16 2023-07-04 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
US10995121B2 (en) 2014-07-16 2021-05-04 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
US11091779B2 (en) 2015-02-10 2021-08-17 Oregon Health & Science University Methods and compositions useful in generating non canonical CD8+ T cell responses
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US10532099B2 (en) 2016-10-18 2020-01-14 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
US11305015B2 (en) 2016-10-18 2022-04-19 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules

Also Published As

Publication number Publication date
AU3910097A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
US5676950A (en) Enterically administered recombinant poxvirus vaccines
WO1999007869A1 (fr) Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite
Bender et al. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza
Moss et al. Vaccinia virus expression vectors
JP3826055B2 (ja) 組換えアビポックスウイルスによる免疫方法
EP0821583B1 (fr) Vaccins adn contre les infections causees par le rotavirus
Maassab et al. The development of live attenuated cold‐adapted influenza virus vaccine for humans
US10029005B2 (en) Bivalent swine influenza virus vaccine
KR20090117697A (ko) 조류 독감용 재조합 변형된 백시니아 바이러스 안카라 (ｍｖａ)-기반 백신
CN102740880A (zh) 基于重组修饰的安卡拉痘苗（mva）病毒的通用流感疫苗
JP2006316072A (ja) Ｄｎａ転写ユニットの接種による免疫化
Meitin et al. Enteric immunization of mice against influenza with recombinant vaccinia.
US5766601A (en) Cross-reactive influenza a immunization
WO2010058236A1 (fr) Vaccin recombinant à vecteur viral inactivé
JP2000501930A (ja) 組換体ポックスウイルス―ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法
CN101087886A (zh) 疱疹性口炎病毒、其载体和其免疫原性组合物的协同减毒
Kammer et al. Rabies vaccines: from the past to the 21st century
US20120003263A1 (en) Recombinant raccoon pox virus vaccine against highly pathogenic avian influenza
EP1167530A9 (fr) PROTEINE DE FUSION DE PVX CAPSID ET UN ANTIGENE, PARTICULES CHIMERIQUES LE PRESENTANT, PLANTES infecté par le virus ET LEUR UTILISATION
Taylor et al. The role of poxvirus vectors in influenza vaccine development
CZ127394A3 (en) Replication-capable recombinant virus, process of obtaining thereof and vaccine composition
RU2215035C2 (ru) Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты)
Ramya et al. Rabies prophylactic approaches
Marshall Immunization against viral infections
NL2014148B1 (en) Combination vaccine for camelids.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA